- Inhibitory Selectivity
- TLR Inhibitors (5)
- New TLR Products
|Catalog No.||Information||Product Use Citations||Product Validations|
GS-9620 is a potent and selective orally active small molecule agonist of Toll-like receptor 7.
CA-4948 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades, and demonstrates pharmacodynamic and antitumor activity in in vitro and in vivo nonclinical models.
Resiquimod is an immune response modifier that acts as a potent TLR 7/8 agonist. Phase 2.
Motolimod (VTX-2337) is a selective and potent Toll-like receptor (TLR) 8 agonist with EC50 of 100 nM, > 50-fold selectivity over TLR7. Phase 2.
Takinib is a potent and selective TAK1 inhibitor with an IC50 of 9.5 nM, more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively.